

**Applicant Initiated Interview Request Form**

Application No.: 09/889,802 First Named Applicant: Kreutzer  
Examiner: Brian Whiteman Art Unit: 1635 Status of Application: After Final

**Tentative Participants:**

- (1) Brian Whiteman (2) Karen Lacourciere  
(3) Kathleen Williams (4) Amy Decloux

Proposed Date of Interview: March 2004 Proposed Time: either (AM/PM)

**Type of Interview Requested:**

- (1) ☐ Telephonic (2) ☐ Personal (3) ☐ Video Conference

Exhibit To Be Shown or Demonstrated: ☐ YES ☐ NO

If yes, provide brief description: \_\_\_\_\_

**Issues To Be Discussed**

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached

**Brief Description of Arguments to be Presented:**


If the attached second after-final amendment does not render  
the application in condition for allowance, Applicants respectfully  
request an interview to discuss outstanding issues.

An interview was conducted on the above-identified application on \_\_\_\_\_.

**NOTE:**

This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

 \_\_\_\_\_  
(Applicant/Applicant's Representative Signature) (Examiner/SPE Signature)

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



Atty. Docket No.: 20200/2092 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kreutzer, et al.  
Serial No.: 09/889,802  
Filed: September 17, 2001  
Entitled: Compositions and Methods for  
Inhibiting the Expression of a Defined  
Gene.

Examiner: Brian A Whiteman  
Group Art Unit: 1635  
Conf. No.: 8835

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV242752939US** on this date, **March 1, 2004**, postage prepaid, in an envelope addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen Williams

Name of Person Mailing

Signature of Person Mailing Paper

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT OF SUBSTANCE OF EXAMINER INTERVIEW**

Sir:

This is filed in response to the Interview Summary mailed on February 3, 2004. Applicants thank Examiner Brian Whiteman for the courtesy of a telephonic interview with the undersigned attorney on January 6, 2004, the substance of which is summarized below.

In the interview, Applicants' representative asked the examiner to reconsider Applicants' position that the cited art does not anticipate the instant claims. Specifically, Applicant requested reconsideration of the cited article by Alfonzo et al. as art because it does not meet all the limitations of the instant claims, including the limitation of the claimed oligoribonucleotide's being complementary to a mammalian target gene.


Applicant also requested reconsideration of the cited patent by Kmiec et al. on the grounds that Kmiec et al does not teach an oligoribonucleotide comprising two separate strands, nor does Kmiec et al teach an oligoribonucleotide which comprises linked strands which are self complementary AND fully complementary to the target gene. At the end of the discussion, the


examiner agreed to consider if the prior art rejections of record would be obviated by an amendment in which the independent claims were amended to recite an isolated oligoribonucleotide consisting of two separate RNA strands that are self-complementary and fully complementary to the target gene.

It is believed that no fees are due. However, if overlooked, the Commissioner for Patents is hereby authorized to charge all fees in the total amount to Deposit Account 16-0085, Reference No. 20200/2092.

Respectfully submitted,

Date: 3/1/04

  
Name: Kathleen Williams  
Registration No.: 34,380  
Customer No.: 29933  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel. (617) 239-0100



03-02-04

AF=Image  
1600

Atty. Docket No.: 20200/2092

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kreutzer, et al.  
Serial No.: 09/889,802  
Filed: September 17, 2001  
Entitled: Compositions and Methods for  
Inhibiting the Expression of a Defined  
Gene.

Examiner: Brian A Whiteman  
Group Art Unit: 1635  
Conf. No.: 8835

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV242752939US** on this date, **March 1, 2004**, postage prepaid, in an envelope addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen Williams

Name of Person Mailing

Signature of Person Mailing Paper

**Mail Stop AF**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**TRANSMITTAL LETTER**

Enclosed for filing the above-identified patent application, please find the following documents:

1. Statement of Substance of Examiner Interview;
2. Amendment After Final Rejection;
3. Applicant-Initiated Interview Request Form; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 20200/2092. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date:

3/1/04

Name: Kathleen Williams

Registration No.: 34,380

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel. (617) 239-0100